(Q35771147)

10 August 2017

1 reference

title

Beyond chronic myelogenous leukemia: potential role for imatinib in Philadelphia-negative myeloproliferative disorders (English)

1 reference

10 August 2017

1 reference

2

Hagop Kantarjian

1 reference

10 August 2017

1

Jorge Cortes

1 reference

PubMed ID

15139047

10 August 2017

language of work or name

English

0 references

publication date

1 May 2004

1 reference

10 August 2017

1 reference

10 August 2017

100

1 reference

10 August 2017

10

1 reference

10 August 2017

2064-2078

1 reference

c-kit Point mutation in patients with myeloproliferative disorders

10 August 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

Cytogenetic studies of bone marrow fibroblasts cultured from patients with myelofibrosis and myeloid metaplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

NIH conference. The idiopathic hypereosinophilic syndrome. Clinical, pathophysiologic, and therapeutic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

The Philadelphia chromosome negative chronic myeloproliferative disorders: a practical overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Polycythemia vera: a comprehensive review and clinical recommendations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Characteristics and outcome of patients with Philadelphia chromosome negative, bcr/abl negative chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The hypereosinophilic syndrome and the biology of cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Clinical, genetic, and therapeutic insights into systemic mast cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Tyrosine kinase fusion genes in chronic myeloproliferative diseases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Increased intraplatelet levels of platelet-derived growth factor and transforming growth factor-beta in patients with myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Biology and genetic aspects of gastrointestinal stromal tumors: KIT activation and cytogenetic alterations.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Stem cell factor induces eosinophil activation and degranulation: mediator release and gene array analysis.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Functional interaction of erythropoietin and stem cell factor receptors is essential for erythroid colony formation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The protein tyrosine kinase family of the human genome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Life expectancy of patients with chronic nonleukemic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Cytogenetic and molecular genetic aspects of essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Myelofibrosis with myeloid metaplasia: clinical and haematological parameters predicting survival in a series of 133 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The forgotten myeloproliferative disorder: myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Polycythemia vera: the natural history of 1213 patients followed for 20 years. Gruppo Italiano Studio Policitemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Polycythemia vera: myths, mechanisms, and management

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Diagnosis and treatment of polycythemia vera and possible future study designs of the PVSG.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The Italian Consensus Conference on Diagnostic Criteria for Myelofibrosis with Myeloid Metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The hypereosinophilic syndrome revisited

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Diagnostic criteria and classification of mastocytosis: a consensus proposal

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Diffuse cutaneous mastocytosis responding to cyproheptadine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The role of tyrosine phosphorylation in proliferation and maturation of erythroid progenitor cells--signals emanating from the erythropoietin receptor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Imatinib mesylate inhibits autonomous erythropoiesis in patients with polycythemia vera in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Outcome of 154 patients with severe aplastic anemia who received transplants from unrelated donors: the Japan Marrow Donor Program.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Polycythemia vera responds to imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Results of imatinib mesylate therapy in patients with refractory or recurrent acute myeloid leukemia, high-risk myelodysplastic syndrome, and myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Phase 2 trial of imatinib mesylate in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Platelet factor 4 enhances generation of activated protein C in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Treatment of hypereosinophilic syndrome with imatinib mesilate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Imatinib for systemic mast-cell disease

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

The World Health Organization (WHO) classification of the myeloid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Mast cell proliferative disorders: current view on variants recognized by the World Health Organization

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

A Polycythemia Vera Updated: Diagnosis, Pathobiology, and Treatment.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

European Collaboration on Low-dose Aspirin in Polycythemia Vera (ECLAP): a randomized trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Successful treatment of anemia in idiopathic myelofibrosis with recombinant human erythropoietin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Risks and benefits of splenectomy in myelofibrosis with myeloid metaplasia: a retrospective analysis of 26 cases.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.20211

7 January 2021

Identifiers

DOI

10.1002/CNCR.20211

1 reference

10 August 2017

1 reference

PubMed ID

15139047